cimzia (certolizumab pegol) recall — Ucb Biosciences Inc. (Class II)

Ucb Biosciences Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling cimzia (certolizumab pegol) — a Class II recall, initiated 2026-05-08 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0546-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Assurance of Sterility”. From the product description, the form is kit, the package is described as 3 cartons and it is marked Rx only. 3 National Drug Code numbers are printed in the record: 50474-710-79, 50474-710-80 and 50474-710-81. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in GA, United States. It is the only recall number the FDA has filed under event ID 98915. 19 days separate the firm's initiation date from the FDA's report date on this record. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0546-2026
FDA event ID 98915
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Ucb Biosciences Inc.
Recall initiated 2026-05-08
Reported by FDA 2026-05-27
Report lag 19 days from initiation to report
Distribution US Nationwide. — Nationwide (US)
Firm location on record GA, United States
Product description (source) cimzia (certolizumab pegol), 2x200mg/mL PREFILLED SYRINGES (2 single-dose), Rx ONLY, Manufactured by: UCB Inc., Smyrna, GA 30080, a) NDC 50474-710-79, b) Professional sample, NDC 50474-710-80; c) 3 cartons, STARTER KIT, NDC 50474-710-81.

Reason reported by FDA

Lack of Assurance of Sterility

5 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 32-word product description above; each is a literal substring of it.

Product named cimzia (certolizumab pegol)
Form Kit
Package 3 cartons
NDC 50474-710-79 · 50474-710-80 · 50474-710-81
Marketing category Rx only
Manufactured by UCB Inc., Smyrna

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Atomoxetine Capsules HCL, 10 mgD-0538-2026Safecor Health, LLCClass II2026-05-27
Liraglutide Injection, 18 mg/3 mLD-0541-2026Lupin Pharmaceuticals Inc.Class II2026-05-27
Gas-X, 125 mgD-0542-2026Haleon US Holdings LLCClass II2026-05-27
Estradiol Gel, 0.1%D-0543-2026Ani Pharmaceuticals, Inc.Class II2026-05-27
Erythromycin Tablets, 250 mgD-0544-2026Zydus Pharmaceuticals (usa) IncClass II2026-05-27
Erythromycin Tablets, 500 mgD-0545-2026Zydus Pharmaceuticals (usa) IncClass II2026-05-27
fentaNYL Citrate, 2,2500 mcg/50mLD-0548-2026Integradose Compounding Services LLCClass II2026-05-27
Vitamin B-Complex, 799 mcg/5mLD-0549-2026Safecor Health, LLCClass II2026-05-27

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-27 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Oasis Tears PF, 10mLD-0525-2026Oasis Medical, Inc.10mL · Eye Drops2026-05-20
Buprenorphine Hydrochloride, 0.3mg/mLD-0527-2026Endo Usa, Inc.0.3mg/mL · Injection2026-05-20
Ascend Laboratories, 25 mgD-0547-2026Ascend Laboratories, LLC25 mg · Extended-Release Tablets2026-05-20
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.1.5% · Solution2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.2.5% · Solution2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.30 mg · Delayed-Release Capsules2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.60 mg · Delayed-Release Capsules2026-05-13
Duloxetine Delayed-Release Capsules, 20 mgD-0516-2026Ajanta Pharma Ltd.20 mg · Delayed-Release Capsules2026-05-13

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 50474-710-79, 50474-710-80 and 50474-710-81 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Ucb Biosciences Inc. (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0546-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0546-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-27
Ingested
2026-08-22
Record hash
ab4329aee2e0d42d

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.